What CeleCor Therapeutics does

CeleCor Therapeutics is a privately held, pre-revenue clinical-stage biopharmaceutical company founded to develop treatments for ST-segment elevation myocardial infarction (STEMI) at the first point of medical contact. The company's single core asset is zalunfiban (brand name Disaggpro™), a next-generation, small-molecule inhibitor of the platelet GPIIb/IIIa receptor invented by Barry S. Coller, MD at The Rockefeller University. Zalunfiban is designed to be administered as a subcutaneous injection by medical first responders or emergency department staff, reaching maximal antiplatelet effect within roughly 15 minutes and wearing off in about two hours — a pharmacokinetic profile explicitly engineered to enable pre-hospital STEMI treatment before primary percutaneous coronary intervention (PCI). Unlike legacy GPIIb/IIIa inhibitors that require IV loading plus infusion-pump delivery, zalunfiban is delivered in under 1 mL by simple subcutaneous injection, blocks platelet aggregation driven by thrombin, thromboxane A2, and ADP, and was designed to reduce the risk of thrombocytopenia.

The clinical evidence base is the CeleBrate trial, a pivotal Phase 3 blinded, randomized, placebo-controlled study that enrolled 2,467 patients at 45 sites across the United States, Canada, Mexico, and Europe. The trial met both primary efficacy and safety endpoints, demonstrating approximately a 21% reduction in the composite of severe outcomes (death, larger MI, stroke, reinfarction, stent thrombosis, or heart failure) when zalunfiban was administered at first medical contact, with no significant increase in major bleeding. CeleCor has secured FDA Fast Track designation (2023), Rolling Review status (January 2026), and completed submission of its NDA to the FDA on June 24, 2026. Phase 3 results were published in NEJM Evidence and presented at the AHA Scientific Sessions in November 2025.

Commercially, CeleCor is preparing for launch by appointing Michael Moye (ex-Idorsia, Shire, J&J) as Chief Commercial Officer and intends to distribute zalunfiban through standard pharmaceutical channels to hospitals, emergency departments, and EMS/ambulance services. Revenue will be generated exclusively through product sales contingent on FDA approval; the company has raised approximately $45.5 million to date via exempt securities offerings. With 1–10 employees and a founder/serial-entrepreneur CEO (Robert Hillman, PhD) alongside the molecule's inventor, CeleCor operates as a focused, single-asset biotech targeting the ~750,000 STEMI events occurring annually in the US — an indication in which at least half of deaths occur pre-hospital and 83% of transferred patients miss American Heart Association time-to-treatment guidelines.

Name

CeleCor Therapeutics

Legal name

CeleCor Therapeutics, Inc.

Website

https://celecor.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

CeleCor Therapeutics is a pre-revenue biopharmaceutical company developing zalunfiban (Disaggpro™), a subcutaneous GPIIb/IIIa platelet inhibitor for pre-hospital treatment of STEMI heart attacks. The company completed its NDA submission to the FDA in June 2026.

Ownership category

akta.pro rank

Product category

Cardiovascular Pharmaceuticals

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Platelet inhibitor therapy
• Acute myocardial infarction
• STEMI drug development
• Pre-hospital cardiac treatment
• Cardiovascular pharmaceuticals

Headquarters

HQ city

Del Mar

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: As a pre-revenue pharmaceutical company, CeleCor's business model will be based on commercialization of zalunfiban (Disaggpro™) upon FDA approval. The company will generate revenue through product sales of its approved drug for STEMI heart attack treatment.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

CeleCor Therapeutics is a clinical-stage biopharmaceutical company developing zalunfiban (Disaggpro™), an investigational next-generation GPIIb/IIIa platelet inhibitor designed for subcutaneous administration at the first point of medical contact for the treatment of ST-segment elevation myocardial infarction (STEMI) heart attacks. The drug is intended for use by medical first responders, ambulance crews, and emergency department staff in pre-hospital settings before patients reach the cardiac catheterization laboratory. Following positive Phase 3 CeleBrate results, the company has filed an NDA with the FDA.

Product overview

CeleCor Therapeutics is a biopharmaceutical company with a single core product focus: zalunfiban (brand name Disaggpro™), an investigational next-generation GPIIb/IIIa platelet inhibitor specifically designed for pre-hospital treatment of STEMI heart attacks. The product is administered as a subcutaneous injection by medical first responders or emergency department staff, reaching maximal effect within 15 minutes. The company's clinical development program centers on the CeleBrate Phase 3 trial, which demonstrated positive efficacy and safety outcomes and led to FDA New Drug Application submission in 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Disaggpro: Brand name for zalunfiban, the investigational drug for STEMI heart attacks

Products and services

• Zalunfiban (Disaggpro™) Investigational next-generation GPIIb/IIIa platelet inhibitor designed for pre-hospital, subcutaneous administration at the first point of medical contact (home, ambulance, or emergency department) for the treatment of STEMI heart attacks. Reaches maximal antiplatelet effect within 15 minutes, with the effect wearing off in approximately two hours, administered in less than 1 mL volume. Intended for use by medical first responders, EMS personnel, and emergency department staff before patients reach the cardiac catheterization laboratory.

Quantifiable outcome

• Phase 3 CeleBrate trial showed approximately 21% reduction in risk of experiencing severe heart attack complications (larger MI, death, stroke, reinfarction, stent thrombosis, or heart failure) when zalunfiban administered at first point of medical contact
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• FDAcoreStrategic or Co-development Partner · 24 June 2026
• FDA (Rolling Review)coreStrategic or Co-development Partner · 1 January 2025
• FDA (Fast Track)coreStrategic or Co-development Partner · 1 September 2023

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cytokinetics: Late-stage cardiovascular drug developer (omecamtiv mecarbil and aficamten in heart failure and HCM). Comparable as a small-cap U.S. cardiovascular therapeutics company advancing a single registrational asset through Phase 3 toward commercialization, with similar capital-raising dynamics and a CV-focused scientific leadership profile.
• Esperion Therapeutics: Commercial-stage cardiovascular biopharmaceutical company focused on lipid management (Nexletol/Nexlizet). Relevant as a U.S. small/mid-cap cardiovascular drug company that has navigated the transition from late-stage development to commercial launch in a therapy area dominated by large incumbents.
• Cardurion Pharmaceuticals: Private, Boston-based cardiovascular drug development company advancing novel therapies for heart failure and other CV diseases. Closely comparable as a privately held, single-therapeutic-area cardiovascular developer with a lean team and late-stage clinical programs.
• Tenaya Therapeutics: Clinical-stage biotechnology company developing therapeutics for heart disease, including gene therapies for genetic cardiomyopathies. Comparable as a small-cap cardiovascular therapeutics developer advancing novel, disease-modifying modalities through clinical trials in a similar capital-constrained environment.
• Lexeo Therapeutics: Clinical-stage cardiovascular-focused gene therapy company with programs in cardiomyopathies and other cardiac conditions. Comparable as a small U.S. cardiovascular drug developer advancing a focused pipeline toward registrational studies, with similar reliance on capital markets and partnership optionality.
• Verve Therapeutics: Clinical-stage cardiovascular biopharmaceutical company developing in vivo gene editing medicines for atherosclerotic cardiovascular disease. Comparable as a high-profile, capital-intensive cardiovascular drug developer targeting durable disease modification in a large CV population.
• Milestone Pharmaceuticals: Cardiovascular specialty pharmaceutical company developing etripamil for paroxysmal supraventricular tachycardia and other acute cardiovascular indications. Comparable as a small-cap cardiovascular drug developer focused on an acute-care, hospital/EMS-adjacent treatment paradigm with similar launch-execution profile.
• Madrigal Pharmaceuticals: Cardiometabolic-focused biopharmaceutical company that brought resmetirom (Rezdiffra) to FDA approval for MASH with significant cardiovascular comorbidity. Comparable as a small-cap U.S. cardiovascular-adjacent drug developer that successfully transitioned from late-stage development to a commercial launch built around a single high-impact asset.

Emerging players

• Anthos Therapeutics: Clinical-stage biopharmaceutical company developing abelacimab, an anti-factor XI monoclonal antibody for thrombosis prevention. Comparable as a developer of a next-generation antithrombotic agent targeting the pre-hospital and hospital cardiovascular settings, with overlapping mechanism rationale.

Broad incumbents

• AstraZeneca: Global pharmaceutical company and incumbent in the antiplatelet and broader cardiovascular market through Brilinta (ticagrelor) and Alexion's andexanet alfa. Relevant as the dominant established player whose standard-of-care therapies CeleCor must integrate with or displace, and as a likely potential strategic acquirer or partner.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/celecor

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CeleCor Therapeutics